New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus

More on Obesity

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• Low-carb telemedicine links to fewer cardiovascular events

  Cardiology and Therapy · 4 Oct 2026